BeiGene, Ltd. (ONC)

Market Cap	25.47B
Revenue (ttm)	4.18B
Net Income (ttm)	-392.37M
Shares Out	107.95M
EPS (ttm)	-3.70
PE Ratio	n/a
Forward PE	94.65
Dividend	n/a
Ex-Dividend Date	n/a

Volume	456,650
Open	236.60
Previous Close	232.25
Day's Range	232.34 - 238.01
52-Week Range	141.31 - 287.88
Beta	0.35
Analysts	Strong Buy
Price Target	326.43 (+38.35%)
Earnings Date	May 7, 2025

About ONC

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a mo...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 11,000
• Stock Exchange: NASDAQ
• Ticker Symbol: ONC
• Website: https://www.beigene.com

Financial Performance

In 2024, BeiGene's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Analyst Forecast

According to 7 analysts, the average rating for ONC stock is "Strong Buy." The 12-month stock price forecast is $326.43, which is an increase of 38.35% from the latest price.

Price Target

$326.43

(38.35% upside)

Analyst Consensus: Strong Buy